Economic aspects of Helicobacter pylori eradication therapy - Where are we now?;Ökonomische aspekte der Helicobacter-pylori-eradikation - Eine standortbestimmung

Gesundheitsokonomie und Qualitatsmanagement

Volumn 6, Issue 5, 2001, Pages 145-151

  Treiber, G ^a   Malfertheiner, P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Economy; Eradication; Helicobacter pylori

Indexed keywords

ANTIGEN SPECIFICITY; BACTERIAL INFECTION; BREATH ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DYSPEPSIA; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; FECES ANALYSIS; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; PEPTIC ULCER; PREVALENCE; RELIABILITY; REVIEW;

EID: 0035188057     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17747     Document Type: Review

References (32)

1. Treatment of Helicobacter pylori infection
2. The influence of drug dosage on Helicobacter pylori eradication. A cost- effectiveness analysis
3. Treatment of Helicobacter pylori infection: A review of the world literature
4. Evaluation of treatment regimens to cure Helicobacter pylori infection - Meta analysis
5. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection
6. A systematic review of Helicobacter pylori eradication therapy - The impact of antimicrobial resistance on eradication rates
7. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori
8. Treating H. pylori shorter than one week - A real future perspective?
9. The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole
10. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer
11. Varying efficacy of Helicobacter pylori eradication regimens: Cost effectiveness study using a decision analysis model
12. Diagnostische verfahren bei Helicobacter pylori-infektion
13. Alternative management strategies for patients with suspected peptic ulcer disease
14. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori
15. Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers - A cost-effectiveness analysis
16. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. Helicobacter pylori in peptic ulcer disease
17. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: Clinical and economic effects
18. A cost analysis of alternative treatments for duodenal ulcer
19. 2-receptor anatagonist maintenance therapy versus Helicobacter pylori eradication therapy
20. Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer
21. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization
22. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: Results of a randomized, double-blind, multicenter trial
23. Treshold analysis of Helicobacter pylori therapy
24. Endoscopy for Helicobacter pylori sero-negative young dyspeptic patients: An economic evaluation based on a randomized trial
25. Management strategies for Helicobacter pylori - Seropositive patients with dyspepsia: Clinical and economic consequences
26. Cost effectiveness of screening for and eradication of helicobacter pylori in management of dyspeptic patients under 45 years of age
27. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects
28. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials
29. Review article: Medical decision models of Helicobacter pylori therapy to prevent gastric cancer
30. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer
31. Helicobacter-eradikation: Eine nicht bezahlbare sisyphusarbeit
32. Helicobacter pylori vaccine development and use: A cost-effectiveness analysis using the Institute of Medicine Methodology